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 2 
ABSTRACT  The early replication of certain prion strains within the Peyer’s patches 20 
in the small intestine is essential for the efficient spread of disease to the brain after 21 
oral exposure.  Our data show that orally-acquired prions utilise specialised gut 22 
epithelial cells known as M cells to enter Peyer’s patches.  M cells express the 23 
cellular isoform of the prion protein, PrPC, and this may be exploited by some 24 
pathogens as an uptake receptor to enter Peyer’s patches.  This suggested that 25 
PrPC might also mediate the uptake and transfer of prions across the gut epithelium 26 
into Peyer’s patches in order to establish infection.  Furthermore, the expression 27 
level of PrPC in the gut epithelium could influence the uptake of prions from the 28 
lumen of the small intestine.  To test this hypothesis, transgenic mice were created 29 
in which deficiency in PrPC was specifically restricted to epithelial cells throughout 30 
the lining of the small intestine.  Our data clearly show that efficient prion 31 
neuroinvasion after oral exposure occurred independently of PrPC expression in 32 
small intestinal epithelial cells.  The specific absence of PrPC in the gut epithelium 33 
did not influence the early replication of prions in the Peyer’s patches or disease 34 
susceptibility.  Acute mucosal inflammation can enhance PrPC expression in the 35 
intestine, implying the potential to enhance oral prion disease pathogenesis and 36 
susceptibility.  However, our data suggest that the magnitude of PrPC expression in 37 
the epithelium lining the small intestine is unlikely to be an important factor which 38 
influences the risk of oral prion disease susceptibility.   39 
 40 
IMPORTANCE  The accumulation of orally-acquired prions within Peyer’s patches 41 
in the small intestine is essential for the efficient spread of disease to the brain.  42 
Little is known of how the prions initially establish infection within the Peyer’s 43 
patches.  Some gastrointestinal pathogens utilize molecules such as the cellular 44 
prion protein, PrPC, expressed on gut epithelial cells to enter Peyer’s patches.  45 
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 3 
Acute mucosal inflammation can enhance PrPC expression in the intestine, implying 46 
the potential to enhance oral prion disease susceptibility.  We used transgenic mice 47 
to determine whether the uptake of prions into Peyer’s patches was dependent upon 48 
PrPC expression in the gut epithelium.  We show that orally-acquired prions can 49 
establish infection in Peyer’s patches independently of PrPC expression in gut 50 
epithelial cells.  Our data suggest that the magnitude of PrPC expression in the 51 
epithelium lining the small intestine is unlikely to be an important factor which 52 
influences oral prion disease susceptibility.   53 
 54 
Key words  prions, transmissible spongiform encephalopathies, PrP, intestine, gut 55 
epithelium, Peyer’s patches 56 
 57 
58 
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 4 
Introduction 59 
Prions cause chronic neurodegenerative diseases that affect humans and some 60 
domesticated and free-ranging animal species to which there are no treatments.  61 
Bovine spongiform encephalopathy (BSE) prions also have zoonotic potential (1), 62 
exerting high societal and economic costs.  The precise nature of the infectious 63 
prion is uncertain, but an abnormal, relatively proteinase-resistant isoform (PrPSc) of 64 
the host cellular prion protein (PrPC), co-purifies with prion infectivity in diseased 65 
tissues (2), and host cells must express cellular PrPC to sustain prion infection (3).   66 
 Many natural prion diseases are acquired by oral consumption of 67 
contaminated food or pasture.  The gut-associated lymphoid tissues (GALT) within 68 
the lining of the intestine such as the tonsils, Peyer’s patches, appendix, colonic and 69 
caecal patches, together with the mesenteric lymph nodes (MLN), help to provide 70 
protection against intestinal pathogens.  However, orally-acquired prions exploit the 71 
GALT to achieve host infection (4-8).  The early replication of prions within Peyer’s 72 
patches in the small intestine is essential for their efficient spread of from the gut to 73 
the brain (termed neuroinvasion), as oral prion disease susceptibility is blocked in 74 
their absence (5, 9-11).   75 
Orally-acquired prions utilize an elegant cellular relay in the GALT in order to 76 
establish host infection.  After ingestion, the prions are first transported across the 77 
follicle-associated epithelium (FAE) which covers the lumenal surface of the Peyer’s 78 
patches by M cells (12-16).  The prions are then acquired by mononuclear 79 
phagocytes within the GALT which they appear to use as “Trojan horses” to shuttle 80 
them towards the follicular dendritic cells (FDC) in the B cell follicles (17-19).  The 81 
subsequent replication of the prions upon FDC is essential for efficient 82 
neuroinvasion from the intestine (4, 5, 17, 20).  The prions then infect nearby enteric 83 
nerves before spreading along fibres of the sympathetic and parasympathetic 84 
 o
n
 July 30, 2018 by UNIVERSITY O
F EDINBURG
H
http://jvi.asm.org/
D
ow
nloaded from
 
 5 
nervous systems to the brain where they ultimately cause neurodegeneration and 85 
death (17, 21). 86 
M cells are specialized, highly phagocytic, intestinal epithelial cells that 87 
facilitate the uptake and trans-epithelial transfer of particulate antigens and 88 
microorganisms into the GALT from the gut lumen (22).  The transcytosis of 89 
particulate antigens by M cells is an important initial step in the induction of efficient 90 
mucosal immune responses against certain pathogenic bacteria (23, 24) and the 91 
commensal bacterial flora (25).  However, some orally-acquired bacterial (26-28) 92 
and viral (29, 30) pathogens utilise M cells to achieve host infection.  Prions also 93 
exploit M cells in order to enter Peyer’s patches and establish host infection (13, 16).  94 
Furthermore, the density of M cells in the gut epithelium directly limits or enhances 95 
disease susceptibility.  In the specific absence of M cells, the accumulation of prions 96 
in Peyer’s patches and subsequent spread of the disease to the brain is blocked 97 
(13, 16).  In contrast, increased M-cell density at the time of oral exposure enhances 98 
prion disease susceptibility approx 10 fold by increasing the uptake of prions from 99 
the gut lumen (16).   100 
M cells are considered to express a variety of “immunosurveillance” receptors 101 
on their apical surfaces which enable them to acquire certain pathogens and 102 
antigens.  For example, glycoprotein 2 (GP2) can act as a receptor for FimH+ 103 
bacteria such as Eschericia coli and Salmonella enterica serovar Typhimurium (23).  104 
Uromodulin (also known as Tamm-Horsfall protein) may similarly mediate the 105 
uptake of surface layer protein A+ lactic acid bacteria (31).  Some pathogenic 106 
microorganisms appear to use receptors on M cells to aid host infection.  The 107 
complement C5a receptor is expressed on the apical surface of M cells and aids the 108 
uptake of Yersinia enterocolitica to establish infection (32).  Interactions between the 109 
type A 1 botulinum neurotoxin complex and GP2 on the M-cell surface have also 110 
 o
n
 July 30, 2018 by UNIVERSITY O
F EDINBURG
H
http://jvi.asm.org/
D
ow
nloaded from
 
 6 
been shown to mediate the intestinal translocation of the toxin order to exert its toxic 111 
effects (33).  M cells express the cellular isoform of the prion protein, PrPC, on their 112 
apical surfaces (26, 34).  Data suggest that the pathogenic Gram-negative 113 
bacterium Brucella abortus utilizes the PrPC on the M-cell surface as an uptake 114 
receptor to enter Peyer’s patches (26).   115 
Whether the uptake and transcytosis of prions across the gut epithelium into 116 
Peyer’s patches in order to establish infection predominantly occurs via constitutive 117 
sampling of the lumenal contents, or via binding to specific receptors such as PrPC, 118 
is not known.  Treatments that impede the early accumulation prions within the 119 
GALT can impede their spread to the brain and reduce disease susceptibility (4, 13, 120 
16, 18).  Thus the identification of the molecular factors that facilitate the uptake of 121 
prions into the GALT will help the design of novel intervention targets, and enhance 122 
our understanding of the factors that influence the risk of infection.  Therefore, in the 123 
current study transgenic mice were created in which Prnp expression (encoding 124 
PrPC) was specifically ablated in epithelial cells throughout the lining of the small 125 
intestine.  These mice were then used to determine whether the absence of PrPC 126 
expression in the epithelium lining the small intestine influences oral prion disease 127 
susceptibility and the early replication of prions in the GALT.   128 
 129 
 130 
RESULTS 131 
Conditional ablation of Prnp throughout the small intestinal epithelium.  The 132 
expression of Cre recombinase under the control of the rat Cyp1a1 promoter 133 
element in Cyp1a1-Cre mice has been used in a series of studies to inducibly ablate 134 
the expression of LoxP site-flanked target genes in small intestinal progenitor cells 135 
and intestinal epithelial cells (IEC) following β-naphthoflavone (βNF) treatment (35-136 
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 7 
37).  The FANTOM5 project of the FANTOM consortium (38) has collated a large 137 
collection of cap analysis of gene expression (CAGE) data from multiple mouse 138 
tissues and cells (http://fantom.gsc.riken.jp/zenbu).  We used this publicly available 139 
data resource to compare the expression of levels of Cyp1a1, Gp2 and Prnp in 140 
multiple data sets derived from mouse FAE, M cells, lymphocytes and leukocytes, 141 
and brain-derived cells.  This analysis confirmed that Cyp1a1 and Prnp were also 142 
expressed highly in the FAE and in GP2+ M cells (Fig. 1).  However, Cyp1a1 143 
expression was absent in B cells, T cells and macrophages as well as brain-derived 144 
microglia, astrocytes and neurons (Fig. 1).   145 
 Here, Cyp1a1-Cre mice were crossed with PrnpF/F mice which carry a 146 
“floxed” Prnp gene (39) to enable the inducible ablation of Prnp specifically in IEC.  147 
Since the reliable detection of PrPC in the gut epithelium by immunohistochemistry 148 
(IHC) is technically challenging, these mice were additionally crossed with 149 
ROSA26F/F reporter mice (40) to enable the cellular-specificity of the Cre-mediated 150 
gene ablation to be readily assessed by histological assessment of β-galactosidase 151 
(LacZ) expression.  The resultant progeny Cyp1a1-Cre ROSA26F/F PrnpF/F mice 152 
were termed PrnpΔIEC mice, hereinafter.   153 
 Female PrnpΔIEC mice were treated with βNF (or vehicle alone as a control) 154 
for five days to specifically ablate Prnp expression in IEC and tissues analyzed 14 155 
days later.  Whole-mount histological analysis showed LacZ expression indicative of 156 
efficient Cre-mediated gene recombination throughout the small and large intestines 157 
of βNF-treated PrnpΔIEC mice (Fig. 2a).  Analysis of tissue sections showed strong 158 
LacZ expression in IEC and crypts throughout the small intestine (Fig. 2c).  The 159 
Cre-mediated gene recombination in the small intestinal crypts of βNF-treated 160 
PrnpΔIEC mice was highly efficient (99.5% ± 1.1; Fig. 2e).  In contrast, the Cre-161 
mediated gene recombination in colonic crypts and IEC in the large intestine was 162 
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 8 
less efficient (64.1% ± 8.6; Fig. 2f) and presented as a mosaic pattern (Fig. 2c).  No 163 
other cellular sites of Cre-mediated recombination were observed throughout the 164 
intestines of βNF-treated PrnpΔIEC mice.  LacZ expression was absent within the 165 
submucosa (Fig. 2c), and also in the sub-epithelial dome and FDC-containing B 166 
cell-follicle regions of the GALT (Fig. 2g).  As anticipated, no LacZ expression was 167 
detected throughout the small and large intestines of vehicle-treated PrnpΔIEC control 168 
mice (Fig. 2b, d, e, f, h).  LacZ expression was also undetectable throughout the 169 
small and large intestines of untreated PrnpΔIEC control mice and βNF-treated 170 
PrnpF/F (Cre-deficient) control mice (Fig. 2 e, f).  These data clearly demonstrate 171 
that Cre-mediated gene recombination is restricted to IEC in the small intestines of 172 
βNF-treated PrnpΔIEC mice.    173 
 174 
Effect of IEC-restricted Prnp-ablation on prion accumulation in lymphoid 175 
tissues.  To determine the effects of IEC-specific PrPC-deficiency on oral prion 176 
disease pathogenesis, groups of female PrnpΔIEC mice were treated with βNF for five 177 
days to specifically ablate Prnp expression in IEC.  Untreated PrnpΔIEC mice, 178 
vehicle-treated PrnpΔIEC mice and βNF-treated PrnpF/F (Cre-deficient) mice were 179 
used as controls.  Fourteen days later 10 mice/group were subsequently orally 180 
exposed to ME7 scrapie prions and tissues collected at 70 days post-infection.  The 181 
presence of the prion disease-specific, abnormal accumulations of PrP (referred to 182 
as PrPd) which occur only in the tissues of affected animals was detected by IHC (4, 183 
5, 11, 13, 16, 19, 41-43).  However, since the IHC analysis cannot unequivocally 184 
discriminate between PrPSc and cellular PrPC, paraffin-embedded tissue immunoblot 185 
analysis of adjacent membrane-bound sections was also used to confirm that these 186 
PrPd aggregates contained prion disease-specific, relatively proteinase-K (PK)-187 
resistant PrPSc.  As anticipated, abundant PrPSc accumulations were detected in 188 
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 9 
association with FDC (CD21/35+ cells) in the Peyer’s patches of control PrnpΔIEC 189 
mice (Fig. 3a, arrows, left-hand and middle columns).  Abundant FDC-associated 190 
PrPSc accumulations were also detected in the Peyer’s patches of βNF-treated 191 
PrnpΔIEC mice.   192 
Consistent with the IHC data (Fig. 3a) high levels of prion infectivity were 193 
detected in the Peyer’s patches of mice from each control group (median infectivity 194 
level 6.0-6.6 Log10 intracerebral [IC] infectious dose [ID]50 units/g, n = 2-4 195 
mice/group; Fig 3b).  IEC-restricted Prnp-ablation did not influence the early 196 
accumulation of infectious prions within Peyer’s patches as high levels of prion 197 
infectivity were also detected in tissues from βNF-treated PrnpΔIEC mice (median 198 
infectivity level 6.1 Log10 IC ID50 infectious units/g, n = 4 mice; Fig 3b). 199 
Within weeks after oral exposure, high levels of ME7 scrapie prions first 200 
accumulate upon FDC in the Peyer’s patches and are subsequently disseminated 201 
via the blood and lymph to most other lymphoid tissues including the MLN and 202 
spleen (4, 5, 11, 13, 16, 18, 19, 44).  The levels of prion infectivity detected in the 203 
MLN and spleens from mice from each treatment and control group were also 204 
similar (Fig. 3c & d, respectively).     205 
These data clearly show that IEC-restricted Prnp-ablation does not affect the 206 
early accumulation of orally-acquired prions within Peyer’s patches or their 207 
subsequent dissemination to the MLN or spleen.   208 
 209 
IEC-restricted Prnp-ablation does not influence oral prion disease 210 
susceptibility.  Female PrnpΔIEC mice were treated with βNF for five days to ablate 211 
Prnp expression in IEC, and 14 days later subsequently orally exposed to ME7 212 
scrapie prions.  Untreated PrnpΔIEC mice, vehicle-treated PrnpΔIEC mice and βNF-213 
treated PrnpF/F (Cre-deficient) mice were used as controls.  As anticipated, all of the 214 
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 10 
orally-exposed untreated PrnpΔIEC (control) mice succumbed to clinical prion disease 215 
(mean survival time 307 ± 23 days; median 300 days, n = 10/10; Table 1).  216 
Furthermore, IEC-restricted Prnp-ablation did not affect disease duration (survival 217 
times) or susceptibility as all of the βNF-treated PrnpΔIEC mice also succumbed to 218 
clinical prion disease with similar survival times (mean 306 ± 11 days; median 306 219 
days, n = 12/12, P = 0.673, One-way ANOVA with Dunnett’s post-test; Table 1).   220 
All the brains from the clinically-affected mice in each group displayed the 221 
characteristic spongiform pathology (vacuolation), PrPSc accumulation, astrogliosis 222 
and microgliosis which is associated with terminal infection with ME7 scrapie prions 223 
(Fig. 4a&b).  The severity and distribution of the spongiform pathology was also 224 
similar in the brains of the clinically-affected mice from each group (Fig. 4c).   225 
Together these data clearly show that efficient prion neuroinvasion after oral 226 
exposure occurs independently of PrPC expression in IEC in the small intestine.  227 
 228 
 229 
DISCUSSION 230 
The initial transport of prions across the gut epithelium by M cells into small 231 
intestinal Peyer’s patches is essential to establish efficient infection after oral 232 
exposure (13, 16).  But whether the uptake and translocation of prions across the 233 
gut epithelium involves a specific receptor is uncertain.  Treatments that prevent the 234 
initial replication of prions within the GALT impede the spread of prions to the brain 235 
and reduce disease susceptibility (4, 13, 16, 18).  Thus the identification of the 236 
molecular factors that facilitate the uptake of prions into the GALT will help the 237 
design of novel intervention strategies, and enhance our understanding of the 238 
factors that influence the risk of infection.  Small intestinal M cells express cellular 239 
PrPC on their apical surfaces and this may be used by certain gastronintestinal 240 
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 11 
pathogens as an uptake receptor to infect Peyer’s patches (26, 34).  Independent 241 
IHC-based tracing studies have suggested that orally-administered prion protein can 242 
be transported across the gut epithelium of PrPC-deficient mice (14, 17), but whether 243 
the expression of PrPC on IEC populations contributed to the establishment of host 244 
infection had not been assessed.  Data in the current study clearly show that prion 245 
neuroinvasion after oral exposure occurs independently of PrPC expression in small 246 
intestinal IEC.   247 
Orally-acquired prions replicate first in the small intestinal GALT and 248 
subsequently spread to most other secondary lymphoid tissues including the large 249 
intestinal GALT.  Since oral prion disease susceptibility is substantially reduced in 250 
the specific absence of the small intestinal GALT (11), this suggests that the early 251 
replication of prions within Peyer’s patches is essential to establish efficient host 252 
infection after oral exposure.  The small intestinal GALT also appear to be the 253 
important early sites of prion replication in natural host species (45-47).  Although 254 
we observed highly efficient Cre-mediated gene recombination in intestinal crypts 255 
and IEC throughout the small intestines of βNF-treated PrnpΔIEC mice, the efficiency 256 
in the colon was less efficient and presented as a mosaic pattern (Fig. 2c) (35).  The 257 
less efficient Prnp-ablation in the large intestine was unlikely to have influenced oral 258 
prion disease pathogenesis in the current study, as the large intestinal GALT such 259 
as the colonic patches are not important early sites of prion replication and 260 
neuroinvasion (11).    261 
Despite the potentially widespread exposure of the UK population to BSE-262 
contaminated food in the 1980s, there have fortunately there have been much fewer 263 
clinical cases of variant Creutzfeldt-Jakob disease in humans than the original 264 
estimates suggested (48) (178 definite or probable cases, as of 4th May 2018; (49)).  265 
This implies that additional factors could potentially influence an individual’s 266 
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 12 
susceptibility to oral prion infection by enhancing or impeding the initial uptake of 267 
prions from the gut lumen.  In support of this hypothesis we have shown that stimuli 268 
that increase the density of M cells in the gut epithelium also increase oral prion 269 
disease susceptibility approx 10 fold by enhancing the uptake of prions into Peyer’s 270 
patches (16).  The expression level of PrPC in host cells such as neurones and FDC 271 
directly influences survival times in prion infected mice (43, 50-52).  Acute mucosal 272 
inflammation following oral infection with S. Typhimurium or treatment with dextran 273 
sodium sulphate have each been shown to enhance PrPC expression in the large 274 
intestine, implying the potential to enhance oral prion disease pathogenesis and 275 
susceptibility (53, 54).  Conversely, PrPC expression was reported to be down-276 
regulated in the small intestines of mice treated with the nonsteroidal anti-277 
inflammatory drug indomethacin, and coincided with a modest increase in survival 278 
time after oral exposure to ME7 scrapie prions (55).  Although the cellular sites of 279 
PrPC expression were not determined in the above studies, our data suggest that 280 
the magnitude of PrPC expression in IEC throughout the small intestine is unlikely to 281 
be an important factor which influences the risk of oral prion disease susceptibility.   282 
In sheep with natural scrapie (56) or orally exposed to BSE prions (57), prion 283 
accumulation is first detected in the palantine tonsils in addition to the Peyer’s 284 
patches.  Natural prion disease susceptible host species such as sheep and cervids 285 
also have highly developed olfactory systems which they use to detect food, select 286 
mates and sense predators.  A series of experimental studies in rodents and sheep have 287 
shown that prion infections can be established via the nasal cavity (58, 59) (60).  Thus it 288 
cannot be excluded that soil-bound prions might also be inhaled and infect the host as the 289 
animal forages for food.  Although M cells are present in the epithelia covering the nasal-290 
associated lymphoid tissue (61), studies in hamsters indicate that these prion uptake across 291 
the nasal epithelium occurs independently of M cells (62).  Whether prion uptake across 292 
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 13 
the mucosal surfaces in the upper gastrointestinal and upper respiratory tracts of 293 
natural host species is also PrPC-independent remains to be determined.   294 
In conclusion, we show that oral prion disease neuroinvasion occurs 295 
independently of PrPC expression in IEC in the small intestine.  Whether prions 296 
exploit other receptors on the apical surfaces of M cells to establish host infection is 297 
uncertain.  The specific targeting of vaccine antigens to M cells has been shown to 298 
be an effective method to induce protective antigen-specific mucosal immunity (63).  299 
Mucosal immunization has also been shown to provide promising protection against 300 
oral prion infections in mice (64) and white-tailed deer (65).  Thus, a thorough 301 
understanding of the mechanisms that prions exploit to establish infection within the 302 
GALT may help to identify important factors which influence the disease 303 
susceptibility, or identify novel targets for prophylactic intervention.    304 
 305 
 306 
MATERIALS AND METHODS 307 
Mice.  The following mouse strains were used in this study where indicated: 308 
Cyp1a1-Cre (35); ROSA26F/F reporter strain (40); PrnpF/F mice (strain Prnptm2Tuzi) 309 
which have LoxP sites flanking exon 3 of the Prnp gene (39).  C57BL/Dk mice were 310 
also used where indicated.  All mice were bred and maintained under SPF 311 
conditions.  All studies and regulatory licences were approved by the Institute’s 312 
ethics committee and carried out under the authority of a UK Home Office Project 313 
Licence.  Prior to their use in experiments, the genotype of each mouse was 314 
confirmed by PCR analysis of tail DNA (Table 2).    315 
 316 
β-naphthoflavone treatment.  Where indicated, mice were given five daily 317 
intraperitoneal injections of β-naphthoflavone (80 mg/kg; Sigma-Aldritch, Poole, UK) 318 
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 14 
dissolved in corn oil (Sigma-Aldritch) and analyzed 14 days after the last injection or 319 
used in subsequent experiments.  Where indicated, some mice received either corn 320 
oil alone (vehicle) or no treatment as controls.   321 
 322 
Histological assessment of LacZ expression.  Tissues were first immersed in 323 
LacZ fixative [PBS (pH 7.4) containing 2% paraformaldehyde, 0.2% gluteraldehyde, 324 
0.02% 325 
Nonidet P40, 0.01% sodium deoxycholate, 5 mM EGTA, 2 mM MgCl2] and washed 326 
in LacZ wash buffer [PBS (pH 7.4) containing 0.02% Nonidet P40, 0.01% sodium 327 
deoxycholate, 2 mM MgCL2].  Tissues were subsequently incubated in 15% (wt/vol) 328 
sucrose in PBS overnight followed by a further overnight incubation in 30% (wt/vol) 329 
sucrose in PBS and embedded in Tissue-Tek OCT compound (Bayer PLC, 330 
Newbury, UK).  Serial sections (thickness 8 mm) were cut on cryostat and stained 331 
overnight at with LacZ staining solution (Glycosynth, Warrington, UK).  Staining 332 
reaction was stopped by washing in LacZ wash buffer followed by distilled water. 333 
Sections were counterstained with nuclear fast red (Vector Laboratories, 334 
Peterborough, UK).  Intestinal whole-mounts were prepared luminal side up as 335 
described previously (66), and fixed in ice-cold 2% formaldehyde/0.2% 336 
glutaraldehyde in PBS (pH 7.4) for 1 h before overnight incubation in LacZ staining 337 
solution.    338 
 339 
Prion exposure and disease monitoring.  For oral exposure, mice were fed 340 
individual food pellets dosed with 50 µl of a 1.0 % (w/v) dilution of scrapie brain 341 
homogenate (containing approximately 4.6 Log10 IC ID50 units) prepared from mice 342 
terminally-affected with ME7 scrapie prions according to our standard protocol (11, 343 
16, 19).  During the dosing period mice were individually housed in bedding- and 344 
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 15 
food-free cages with water provided ad libitum.  A single prion-dosed food pellet was 345 
then placed in the cage.  The mice were returned to their original cages (with 346 
bedding and food ad libitum) as soon as the food pellet was observed to have been 347 
completely ingested.  The use of bedding- and additional food-free cages ensured 348 
easy monitoring of consumption of the prion-contaminated food pellet.  Following 349 
prion exposure, mice were coded and assessed weekly for signs of clinical disease 350 
and culled at a standard clinical endpoint.  The clinical endpoint of disease was 351 
determined by rating the severity of clinical signs of prion disease exhibited by the 352 
mice.  Mice were clinically scored as “unaffected”, “possibly affected” and “definitely 353 
affected” using standard criteria which typically present in mice terminal ME7 354 
scrapie prion disease.  Clinical signs following infection with the ME7 scrapie prions 355 
may include: weight-loss, starry coat, hunched, jumpy behaviour (at early onset) 356 
progressing to limited movement, upright tail, wet genitals, decreased awareness, 357 
discharge from eyes/blinking eyes, ataxia of hind legs.  The clinical endpoint of 358 
disease was defined in one of the following ways: i) the day on which a mouse 359 
received a second consecutive “definite” rating; ii) the day on which a mouse 360 
received a third “definite” rating within four consecutive weeks; iii) the day on which 361 
a mouse was culled in extremis.  Prion diagnosis was confirmed by histopathological 362 
assessment of the magnitude of the spongiform pathology (vacuolation) in nine 363 
distinct grey-matter regions of the brain as described (67).   364 
 For bioassay of prion infectivity, individual tissues were prepared as 10 % 365 
(w/v) homogenates and 20 µl was injected IC into each of 4 recipient C57BL/Dk 366 
indicator mice. The prion infectivity titre in each sample was determined from the 367 
mean incubation period in the indicator mice, by reference to a dose/incubation 368 
period response curve for ME7 scrapie-infected spleen tissue serially titrated in 369 
C57BL/Dk indicator mice (68). 370 
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 371 
Immunohistochemisty.  For the detection of disease-specific PrP (PrPd) in 372 
intestines and brains, tissues were fixed in periodate-lysine-paraformaldehyde 373 
fixative and embedded in paraffin wax.  Sections (thickness, 6 µm) were 374 
deparaffinised, and pre-treated to enhance the detection of PrPd by hydrated 375 
autoclaving (15 min, 121ºC, hydration) and subsequent immersion in formic acid 376 
(98%) for 5 min.  Sections were then immunostained with 1B3 PrP-specific pAb.  For 377 
the detection of FDC in intestines deparaffinised sections were first pre-treated with 378 
Target Retrieval Solution (DAKO) and subsequently immunostained with anti-379 
CD21/35 (clone 7G6, BD Biosciences).  Paraffin-embedded tissue immunoblot 380 
analysis was used to confirm that the PrPd detected by immunohistochemistry was 381 
proteinase K-resistant PrPSc (69).  Membranes were subsequently immunostained 382 
with 1B3 PrP-specific pAb.   383 
For the detection of astrocytes, brain sections were immunostained with anti-384 
glial fibrillary acidic protein (GFAP; DAKO, Ely, UK), and to detect microglia sections 385 
were immunostained with anti-ionized calcium-binding adaptor molecule 1 (Iba-1; 386 
Wako Chemicals GmbH, Neuss, Germany).   387 
Following the addition of primary antibodies, biotin-conjugated species-388 
specific secondary antibodies (Stratech, Soham, UK) were applied and 389 
immunolabelling was revealed using either alkaline phoshatase-conjugated to the 390 
avidin-biotin complex (Vector Laboratories, Peterborough, UK) and visualized using 391 
Vector Red (Vector Red), or HRP-conjugated to the avidin-biotin complex (Vector 392 
Laboratories) and visualized with DAB (Sigma).  Sections were counterstained with 393 
haematoxylin to distinguish cell nuclei.   394 
 395 
Immunoblot detection of PrPSc 396 
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Brain homogenates (10% weight/volume) were prepared in NP40 lysis buffer (1% 397 
NP40, 0.5% sodium deoxycholate, 150 mM NaCl, 50 mM TrisHCL [pH 7.5]) and 398 
incubated at 37°C for 1 h with 20 µg/ml PK.  Digestions were halted by addition of 1 399 
mM phenylmethylsulfonyl fluoride.  Samples were then subjected to electrophoresis 400 
through 12% Tris-glycine polyacrylamide gels (Nupage, Life Technologies) and 401 
transferred to PVDF membranes by semi-dry blotting.  PrP was detected using anti-402 
mouse PrP-specific mAb 7A12 (70) followed by horseradish peroxidase-conjugated 403 
goat anti-mouse antibody (Jackson Immunoresearch) and visualised 404 
chemiluminescence (BM Chemiluminescent substrate kit, Roche, Burgess Hill, UK). 405 
 406 
Statistical analyses.  Unless indicated otherwise, data are presented as mean ± 407 
SD and significant differences between groups were sought by Student’s t-test.  408 
Values of P < 0.05 were accepted as significant.   409 
 410 
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FIG 1  Cyp1a1 is expressed in the follicle-associated epithelium and in M cells in the 423 
small intestine.  Comparison of Cyp1a1, Prnp and Gp2 mRNA expression in 424 
individual cell populations in deep cap analysis of gene expression (CAGE) 425 
sequence data from the FANTOM5 project of the FANTOM consortium (38).  Each 426 
bar shows the relative expression level of each gene per million reads in each 427 
sample; RLE normalized tags/million).  The blue hatched box highlights the small 428 
intestine-derived glycoprotein 2-expressing (GP2+) M-cell and the follicle-associated 429 
epithelium datasets.  The red hatched box highlights the brain-derived datasets.   430 
 431 
FIG 2  Cre-mediated gene recombination is restricted to IEC in the small intestines 432 
of βNF-treated PrnpΔIEC mice.  Female PrnpΔIEC mice were treated with β-433 
naphthoflavone (βNF) for five days to specifically ablate Prnp expression in intestinal 434 
epithelial cells and tissues analyzed 14 days later.  PrnpΔIEC mice treated with 435 
vehicle alone (Veh.) were used as controls.  (A, B) Whole-mount histological 436 
analysis of LacZ expression (blue) in the intestines of (A) βNF-treated PrnpΔIEC mice 437 
or (B) vehicle-treated PrnpΔIEC control mice.  S, small intestine. L, large intestine.  438 
(C, D) Histological analysis of LacZ expression (blue) in IEC and crypts in the 439 
intestines of (C) βNF-treated PrnpΔIEC mice or (D) vehicle-treated PrnpΔIEC control 440 
mice.  Sections were counterstained with nuclear fast red to detect cell nuclei (red).  441 
SM, submucosa.  (E, F) Comparison of the % LacZ-expressing crypts in (E) the 442 
small and (F) large intestines, of βNF-treated PrnpF/F mice control mice.  Untreated 443 
PrnpΔIEC mice, vehicle-treated PrnpΔIEC mice and βNF-treated PrnpF/F mice were 444 
used as controls.  Data represent mean % LacZ-expressing crypts/mouse (n = 5 445 
mice/group, 50-105 crypts/mouse).  (G, H) Histological analysis of LacZ expression 446 
(blue) in the Peyer’s patches and colonic patches of (G) βNF-treated PrnpΔIEC mice 447 
or (H) vehicle-treated PrnpΔIEC control mice.   448 
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 449 
FIG 3  Effect of intestinal epithelial cell-restricted Prnp-ablation on prion 450 
accumulation in lymphoid tissues.  Female PrnpΔIEC mice were treated with β-451 
naphthoflavone (βNF) for five days to specifically ablate Prnp expression in intestinal 452 
epithelial cells.  Untreated PrnpΔIEC mice and PrnpΔIEC mice treated with vehicle 453 
alone (Veh.) were used as controls.  Fourteen days later the mice were orally 454 
exposed to ME7 scrapie prions and Peyer’s patches, mesenteric lymph nodes 455 
(MLN) and spleens collected at 70 days post infection.  (A)  Immunohistochemical 456 
analysis revealed high levels of disease-specific PrP (PrPd, red, middle row, arrows) 457 
were detected in association with FDC (CD21/35+ cells, red, upper row) in Peyer’s 458 
patches from mice from each group.  Sections were counterstained with 459 
haematoxylin to detect cell nuclei (blue).  Analysis of adjacent sections by paraffin-460 
embedded tissue immunoblot analysis confirmed the presence of prion-specific PK-461 
resistant PrPSc (blue/black).  Data representative of tissues from 6 mice/group.  (B, 462 
C, D) Prion infectivity levels were assayed in (B) Peyer’s patches, (C) MLN and (D) 463 
spleens from mice from each group collected at 70 days post infection.  Prion 464 
infectivity titres (log10 IC ID50/g tissue) were determined by injection of tissue 465 
homogenates into groups of C57BL/Dk indicator mice (n = 4 recipient mice/tissue).  466 
Each symbol represents data derived from an individual tissue.  Red line, median 467 
prion infectivity titre for groups in which all samples contained >1 log10 IC ID50/g 468 
tissue.  Data below the broken horizontal line indicate disease incidence in the 469 
recipient mice <100% and considered to contain trace levels of prion infectivity.   470 
 471 
FIG 4.  Intestinal epithelial cell-restricted Prnp-ablation does not influence 472 
development of the histopathological signs prion disease in the brains of clinically 473 
affected mice.  Female PrnpΔIEC mice were treated with β-naphthoflavone (βNF) for 474 
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five days to specifically ablate Prnp expression in intestinal epithelial cells.  475 
Untreated PrnpΔIEC mice and PrnpΔIEC mice treated with vehicle alone (Veh.) were 476 
used as controls.  Fourteen days later the mice were orally exposed to ME7 scrapie 477 
prions and culled when they succumbed to clinical prion disease.  (A) High levels of 478 
spongiform pathology (H&E), heavy accumulations of disease-specific PrP, (PrPd, 479 
brown), reactive astrocytes expressing GFAP (brown) and active microglia 480 
expressing IBA1 (brown) were detected in the brains of all orally-exposed mice with 481 
clinical prion disease.  Clin., clinical prion disease status; pos., clinically positive; 482 
individual survival times are shown (dpi, days post infection).  Sections were 483 
counterstained with haematoxylin to detect cell nuclei (blue).  (B) Immunoblot 484 
analysis of brain tissue homogenates confirmed the presence of high levels of prion-485 
specific, relatively proteinase K (PK)-resistant PrPSc within the brains of the 486 
clinically-affected mice from each group.  Samples were treated in the presence (+) 487 
or absence (-) of PK before electrophoresis. After PK treatment, a typical three-band 488 
pattern was observed between molecular mass value of 20–30 kDa, representing 489 
unglycosylated, monoglycosylated, and diglycosylated isomers of PrP (in order of 490 
increasing molecular mass).  (C) The severity and distribution of the spongiform 491 
pathology (vacuolation) within each brain was scored on a scale of 1–5 in nine grey 492 
matter areas: G1, dorsal medulla; G2, cerebellar cortex; G3, superior colliculus; G4, 493 
hypothalamus; G5, thalamus; G6, hippocampus; G7, septum; G8, retrosplenial and 494 
adjacent motor cortex; G9, cingulate and adjacent motor cortex.  Each point 495 
represents the mean vacuolation score ± SD (n = 10-12 mice/group). 496 
 497 
 498 
  499 
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TABLE 1  Prnp-deficiency in the gut epithelium does not influence oral prion disease
susceptibility
Mouse modela
Mean
survival
times
(days±SD)b,c
Median
survival
times
(days)
Clinical
diseased
Histopathological
signs of prion
disease in the
braine
PrnpIEC 307 ± 23 300 10/10 10/10
PrnpIEC + Veh. 303 ± 12 303 10/10 10/10
PrnpIEC + βNF 308 ± 11 306 12/12 12/12
PrnpF/F + βNF 313 ± 19 305 9/9 9/9
a Where indicated, mice were given daily IP injections with β-napthoflavone (βNF) or
corn oil (Vehicle control, Veh.) for 5 days.  Mice were orally exposed to ME7 scrapie
prions 14 days after the last treatment.
b Duration from time of injection with prions to cull at clinical end-point.
c No  statistical  differences  in  survival  times  were  observed  between  groups
(P=0.673; One-way ANOVA with Dunnett’s post-test.  
d Incidence  =  no.  animals  displaying  clinical  signs  of  prion  disease/no.  animals
tested.  
e Incidence = no. animals with histopathological signs of prion disease in the brain
(spongiform pathology)/no. animals tested.  
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TABLE 2  PCR primers used to confirm mouse genotypes
Allele Details Primer sequence
Product 
size/s (bp)
Cre Fwd
Rev
CGAGTGATGAGGTTCGCAAGAACC
 
GCTAAGTGCCTTCTCTACACCTGC
786
LacZ Fwd
Rev
TACCACAGCGGATGGTTCGG
GTGGTGGTTATGCCGATCGC
300
Prnpflox 1
2
3
AATGGTTAAACTTTCGTTAAGGAT
GCCGACATCAGTCCACATAG
GGTTGACGCCATGACTTTC
Recombined
PrnpF 344
   
   PrnpF 210
  
Prnp+ 167
Prnp+ Fwd
Rev 
TCATCCCACGATCAGGAAGATGAG 
ATGGCGAACCTTGGCTACTGGCTG
600
Fwd, forward primer; Rev, reverse primer; Recombined PrnpF, Cre-mediated DNA 
recombined allele
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